By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000

Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:




Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Genentech (RHHBY) Provides Update On Phase 3 MARIANNE Study In People With Previously Untreated Advanced HER2-Positive Breast Cancer 12/19/2014 6:09:33 AM
FDA Breakthrough Status For Genentech (RHHBY)'s Lucentis 12/16/2014 6:33:51 AM
Gilead Sciences, Inc. (GILD) Poaches Genentech (RHHBY) Exec To Head Cancer Drug Program 12/15/2014 8:41:32 AM
Genentech (RHHBY) Submits New Drug Application To FDA For Investigational Cobimetinib Used In Combination With Zelboraf (Vemurafenib) In Advanced Melanoma 12/15/2014 6:02:57 AM
Genentech (RHHBY) Submits NDA For Skin Cancer Med Cobimetinib 12/15/2014 6:01:59 AM
Genentech (RHHBY)'s R&D Chief To Retire; Small Molecule Head Takes Over Top Spot 12/12/2014 6:33:48 AM
Doctors Who Promote More Expensive Eye Drug Are Among The Highest-Paid Genentech (RHHBY) Consultants 12/9/2014 8:21:57 AM
Genentech (RHHBY) To Present Clinical Data From Six Different Medicines At American Society of Hematology Annual Meeting 12/5/2014 9:49:03 AM
Genentech (RHHBY) Defends Supply Shift For Top Cancer Drugs 11/25/2014 7:55:52 AM
FDA Approves Genentech (RHHBY)’s Avastin (Bevacizumab) Plus Chemotherapy To Treat Women With Platinum-Resistant Recurrent Ovarian Cancer 11/17/2014 12:30:18 PM